Barriers to hepatitis C treatment

被引:141
|
作者
McGowan, Christopher E. [1 ]
Fried, Michael W. [1 ]
机构
[1] Univ N Carolina, Sch Med, UNC Liver Ctr, Div Gastroenterol & Hepatol, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
delivery of health care; barriers to care; health services accessibility; hepatitis C; therapy; INJECTION-DRUG USERS; VIRUS-INFECTION; ANTIVIRAL THERAPY; PLUS RIBAVIRIN; CARE; MANAGEMENT; KNOWLEDGE; VETERANS; OUTCOMES; RATES;
D O I
10.1111/j.1478-3231.2011.02706.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Despite the availability of highly effective therapy for hepatitis C virus (HCV) infection, few patients receive treatment. Barriers arising at multiple levels, from diagnosis to specialist referral, may impede the delivery of hepatitis C care. At the patient level, lack of awareness, fear of side effects, poor adherence and comorbid conditions may prevent treatment. For providers, limited knowledge, lack of availability and communication difficulties may be problematic. At the government and payer level, a lack of promotion, surveillance and funding may interfere. Each of these barriers needs to be addressed if wider implementation of antiviral therapy is to be achieved.
引用
收藏
页码:151 / 156
页数:6
相关论文
共 50 条
  • [21] Barriers to accessing care in patients with chronic hepatitis C: the impact of depression
    Evon, D. M.
    Simpson, K. M.
    Esserman, D.
    Verma, A.
    Smith, S.
    Fried, M. W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 32 (09) : 1163 - 1173
  • [22] Supportive Interventions During Treatment of Chronic Hepatitis C A Review of the Literature
    Bailey, Donald E.
    Zucker, Donna M.
    GASTROENTEROLOGY NURSING, 2020, 43 (05) : E172 - E183
  • [23] Clinical drivers in naive patient eligibility for treatment of chronic hepatitis C
    Degasperi, E.
    Aghemo, A.
    JOURNAL OF VIRAL HEPATITIS, 2012, 19 : 3 - 6
  • [24] Successful Integration of Hepatitis C Evaluation and Treatment Services With Methadone Maintenance
    Harris, Kenneth A., Jr.
    Arnsten, Julia H.
    Litwin, Alain H.
    JOURNAL OF ADDICTION MEDICINE, 2010, 4 (01) : 20 - 26
  • [25] Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece
    Papadopoulos, Nikolaos
    Manolakopoulos, Spilios
    Deutsch, Melanie
    Mela, Maria
    Christidou, Aggeliki
    Katoglou, Athina
    Tzourmakliotis, Dimitrios
    Papatheodoridis, George V.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 25 (05) : 587 - 593
  • [26] Chronic Hepatitis C virus infection in Swiss primary care practices: Low case loads-high barriers to treatment?
    Overbeck, Kathrin
    Bruggmann, Philip
    Helbling, Beat
    EUROPEAN JOURNAL OF GENERAL PRACTICE, 2011, 17 (02) : 103 - 108
  • [27] Telaprevir for the treatment of chronic hepatitis C infection
    Muir, Andrew J.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (12) : 1105 - 1114
  • [28] Racial Differences in Hepatitis C Treatment Eligibility
    Melia, Michael T.
    Muir, Andrew J.
    McCone, Jonathan
    Shiffman, Mitchell L.
    King, John W.
    Herrine, Steven K.
    Galler, Greg W.
    Bloomer, Joseph R.
    Nunes, Frederick A.
    Brown, Kimberly A.
    Mullen, Kevin D.
    Ravendhran, Natarajan
    Ghalib, Reem H.
    Boparai, Navdeep
    Jiang, Ruiyun
    Noviello, Stephanie
    Brass, Clifford A.
    Albrecht, Janice K.
    McHutchison, John G.
    Sulkowski, Mark S.
    HEPATOLOGY, 2011, 54 (01) : 70 - 78
  • [29] Hepatitis C treatment in patients with kidney disease
    Fabrizi, Fabrizio
    Aghemo, Alessio
    Messa, Piergiorgio
    KIDNEY INTERNATIONAL, 2013, 84 (05) : 874 - 879
  • [30] Treatment of hepatitis C infection for current or former substance abusers in a community setting
    John-Baptiste, A.
    Varenbut, M.
    Lingley, M.
    Nedd-Roderique, T.
    Teplin, D.
    Tomlinson, G.
    Daiter, J.
    Krahn, M.
    JOURNAL OF VIRAL HEPATITIS, 2009, 16 (08) : 557 - 567